Using ultrasound to evaluate breast cancer biomarkers
Official title: VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients
Run by UNC Lineberger Comprehensive Cancer Center · NCT06878547 · Data updated 2026-11-12
This study is testing whether special ultrasound techniques can help doctors understand how breast tumors behave and respond to chemotherapy in women with either benign or malignant tumors.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 90 Years |
| Sex | Women only |
| Enrollment | 250 (estimated) |
| Sponsor | UNC Lineberger Comprehensive Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, Radiation |
| Locations | 1 site (Chapel Hill, North Carolina) |
| Status | Recruiting |
| Started | March 7, 2025 |
| Main results expected | August 25, 2027 |
| Study ends | February 24, 2028 |
| Registry record updated | June 2, 2026 |
| Trial ID | NCT06878547 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 20-90 with sonographically visible breast lesions rated BI-RADS 4a, 4b, 4c, or 5, or those with BI-RADS 6 lesions undergoing neoadjuvant chemotherapy.
✕Probably not a fit
Patients who may not benefit include those with breast implants, a history of mastectomy, or those unable to provide informed consent.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the correlation between non-invasive ultrasound measurements of tissue stiffness, viscosity, and anisotropy with breast tumor malignancy and response to chemotherapy. It involves two arms: one with women having benign or malignant breast tumors and another with women undergoing neoadjuvant chemotherapy. The research utilizes advanced ultrasound technologies, including Acoustic Radiation Force Impulse (ARFI) and Viscoelastic Response (VisR) ultrasound, to gather data on breast tissue characteristics. The goal is to determine how these ultrasound-derived metrics can aid in cancer diagnosis and staging.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for better diagnosing and staging breast cancer, potentially improving treatment outcomes.
How similar studies have gone: Other studies have shown promise in using ultrasound technologies for breast cancer diagnostics, but this specific approach is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria (Arm 1): * Subjects are 20-90 years of age * Subjects are female * Breast lesion is sonographically visible with B-Mode ultrasound on diagnostic workup * Breast lesion(s) have BI-RADS 4a, 4b, 4c, or 5 rating Exclusion Criteria (Arm 1): * Inability to provide informed consent * Inability to communicate in English * Inability to remain motionless for 15 minutes * Subjects with breast implants * Breast mass is deeper than 4 cm from skin surface * Subjects who are pregnant or lactating * Subjects who have pacemakers or implanted cardioverters * Subjects with a history of mastectomy * Previous biopsy or surgery to the site of the mass, surgical excision of mass of interest * Subject is male Inclusion Criteria (Arm 2): * Subjects are 20-90 years of age * Subjects are female * Breast lesion is sonographically visible with B-Mode ultrasound on diagnostic workup * Breast lesion(s) have BI-RADS 6 rating, subject will be undergoing NAT for stage 2 or 3 malignant breast lesion(s) Exclusion Criteria (Arm 2): * Inability to provide informed consent * Inability to communicate in English * Inability to remain motionless for 15 minutes * Subjects with breast implants * Breast mass is deeper than 4 cm from skin surface * Subjects who are pregnant or lactating * Subjects who have pacemakers or implanted cardioverters * Subjects with a history of mastectomy * Previous biopsy or surgery to the site of the mass, surgical excision of mass of interest * Subject is male
Where it's running
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Caterina Gallippi, PhD — Lampe Joint Department of Biomedical Engineering
- Study coordinator: Desma Jones
- Email: desma_jones@med.unc.edu
- Phone: 919-843-9463
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.